To examine ART-related health outcomes, CDC and three states (Massachusetts, Florida, and Michigan) established the States Monitoring ART (SMART) Collaborative to evaluate maternal and perinatal outcomes of ART and improve state-based ART surveillance. To date, NASS data have been linked with states’ vital records, disease registries, and hospital

discharge data with a linkage rate of 90.2%. The probabilistic linkage methodology used in the SMART Collaborative has been validated and found to be both accurate and efficient. A wide breadth of applied research within the Collaborative is planned or ongoing, including examinations of the impact of insurance mandates on ART use as well as the relationships between ART and birth defects and cancer, among others. The SMART Collaborative is working to improve state-based ART surveillance Savolitinib ic50 by developing state surveillance plans, establishing partnerships, and conducting data analyses. The SB202190 MAPK inhibitor SMART Collaborative has been instrumental in creating linked datasets and strengthening epidemiologic and

research capacity for improving maternal and infant health programs and evaluating the public health impact of ART.”
“Objective. The purpose of this study was to analyze the relationship of 1-h post-glucola (PG) screening results and the need for insulin therapy in women with gestational diabetes (GDM).

Methods. The study group was comprised of women

with GDM treated at a single institution during calendar years 2000-2004. Women with singleton, term (>= 37 weeks gestation), liveborn fetuses were included. The association of 1-h PG results and other perinatal risk factors to the need Peptide 17 mouse for subsequent insulin therapy was analyzed using multivariable logistic regression models.

Results. Of the 1451 women were included in the analysis, 18.1% required insulin treatment. The mean 1-h PG result was 170.0+/-26.1 mg/dl (range 140-414 mg/dl). We determined that a 1-h PG >= 190 mg/dl (p < 0.0001), an obese body mass index (BMI) (p < 0.0001), an overweight BMI (p = 0.0019), prior GDM (p = 0.0019), and prior macrosomia (p = 0.0210) were each highly associated with the need for subsequent insulin therapy during the pregnancy.

Conclusions. A 1-h PG >= 190 mg/dl was strongly associated with the need for insulin therapy in women with GDM. These data may be helpful in counseling and managing women with GDM.”
“In order to develop a practical risk score for 90-day mortality following surgical lung biopsy (SLB) for interstitial lung disease (ILD) we reviewed 311 consecutive patients undergoing SLB for ILD between 2002 and 2009. Postoperative complication, 30-day and 90-day mortality rates were 11.5%, 9% and 10.6% respectively. Univariable and multivariable analyses, validated by bootstrap statistics, were used to identify factors associated with 90-day mortality.